Autor: |
Ivan G. Gordeev, Andrey Alexandrovich Ivashchenko, Alexey P. Ilin, Dmitry V. Kravchenko, Nikolay Filippovich Savchuk, Kirill A. Dmitriev, Nikita V. Lomakin, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Elena N Simakina, Elena A. Merkulova, Natalia V. Vostokova, Natalia A. Papazova, Elena A Smolyarchuk, Alexandre V. Ivachtchenko, Andrew A. Blinow, Elena P. Pavlikova, Tagir A. Sitdekov, Alina N. Egorova, Valeria N Azarova |
Jazyk: |
angličtina |
Rok vydání: |
2020 |
Předmět: |
|
DOI: |
10.1101/2020.07.26.20154724 |
Popis: |
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|